When was PhaseBio Pharmaceuticals founded?

PhaseBio Pharmaceuticals was founded in 2002 and raised its 1st funding round 4 years after it was founded.

Where is PhaseBio Pharmaceuticals located?

PhaseBio Pharmaceuticals is headquartered in Malvern, United States. It is registered at Malvern, Pennsylvania.

How many employees does PhaseBio Pharmaceuticals have?

As of Dec 31, 2021, the latest employee count at PhaseBio Pharmaceuticals is 61.

Is PhaseBio Pharmaceuticals a funded company?

PhaseBio Pharmaceuticals is a funded company, having raised a total of $152M across 11 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 2006.

When was the latest funding round of PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' latest funding was a $***** Series D round on Sep 05, 2018, with participation from 9 investors. Its primary sector is Metabolic Diseases. In United States, the Metabolic Diseases sector has seen $536M in funding in 2026 to date.

What is the annual revenue of PhaseBio Pharmaceuticals?

Annual revenue of PhaseBio Pharmaceuticals is between $10M and $50M as on Dec 31, 2021

Where does PhaseBio Pharmaceuticals rank among its competitors?

PhaseBio Pharmaceuticals ranks 7th amongst 43 active competitors, of which 11 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sernova, which secured $345K in Oct, 2025.

Who are the top competitors of PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept. Among them, Sernova secured the most recent funding round in October, 2025.

PhaseBio Pharmaceuticals - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of novel drugs to treat metabolic and cardiopulmonary disorders. The company has developed therapeutics by using elastin-like biopolymers which have been shown to increase drug half-life and bioavailability while reducing side effects and cost. The product portfolio includes Bentracimab an antiplatelet drug, Pemziviptadil for pulmonary arterial hypertension, PB6440 for hypertension.

Website: www.phasebio.com/
Social
Registered Address: Malvern, Pennsylvania

Key Metrics

Founded Year

2002

Location

Malvern, United States

Stage

Public

Total Funding

$152M in 11 rounds

Latest Funding Round

Series D, Sep 05, 2018, $*****

Investors

New Enterprise Associates & 13 more

Ranked

7^th among 43 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2021

Employee Count

61 as on Dec 31, 2021

Similar Companies

Rhythm Pharmaceuticals & 59 more

Exit Details

Public

View PhaseBio Pharmaceuticals' full profile

PhaseBio Pharmaceuticals is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Phasebio Pharmaceuticals Inc CIN: 1169245 , United States, Active	Jan 09, 2002	$10M - $50M (As on Dec 31, 2021)	-	-
Phasebio Pharmaceuticals, Inc. CIN: 30375697 , United States, Active	Dec 31, 1999	-	39 (As on Dec 31, 2022)	-

PhaseBio Pharmaceuticals got listed on Oct 23, 2018.

Click here to take a look at PhaseBio Pharmaceuticals's IPO in detail

PhaseBio Pharmaceuticals has raised a total funding of $152M over 11 rounds. Its first funding round was on Sep 2006. Its latest funding round was a Series D round on Sep 05, 2018 for $*****. 9 investors participated in its latest round. PhaseBio Pharmaceuticals has 14 institutional investors.

Here is the list of recent funding rounds of PhaseBio Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 05, 2018	9269418	Series D	7927336	4637147	3787273	6316489
Feb 27, 2018	6462155	Grant (prize money)	1704752	5344532	2828595	NIH
Feb 17, 2018	6146340	Grant (prize money)	3718997	8887795	4196200	HHS

Access funding benchmarks and valuations. Sign up today!

View details of PhaseBio Pharmaceuticals's funding rounds and investors

PhaseBio Pharmaceuticals' employee count trend

PhaseBio Pharmaceuticals has 61 employees as of Dec 21. Here is PhaseBio Pharmaceuticals's employee count trend over the years:

Employee count trend for PhaseBio Pharmaceuticals

Uncover PhaseBio Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PhaseBio Pharmaceuticals include Rhythm Pharmaceuticals, MannKind Corp and Corcept. Here is the list of Top 10 competitors of PhaseBio Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
2nd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Deerfield & 1 others	70/100
3rd	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Cornerstone Capital, Longitude Capital & 7 others	68/100
4th	89bio 2018, San Francisco (United States), Acquired	Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders	$60M	Longitude Capital, Orbimed & 3 others	64/100
5th	Sernova 1998, London (Canada), Public	Regenerative medicine to deliver proteins and hormones for disease treatment	-	Evotec, National Research Council Canada & 1 others	61/100
6th	Genfit 1999, Loos (France), Public	Therapeutics for cardiometabolic and neurodegenerative diseases.	-	Eiffel Investment Group, Ridgeback Capital Management ... & 2 others	59/100
7th	PhaseBio Pharmaceuticals 2002, Malvern (United States), Public	Developer of novel drugs to treat metabolic and cardiopulmonary disorders	$152M	Cormorant Asset Management, New Enterprise Associates ... & 12 others	56/100
8th	Verdiva Bio 2024, London (United Kingdom), Series A	Developer of oral and injectable peptide therapies for metabolic diseases	$411M	General Atlantic, Forbion & 5 others	56/100
9th	OptiBiotix Health 2012, York (United Kingdom), Public	Developer of microbial strains for the treatment of human metabolic diseases	-	Seneca EIS Portfolio Fund, Enterprise Ventures ... & 2 others	55/100
10th	NGM Biopharmaceuticals 2007, San Francisco (United States), Public	Developer of biologics for the treatment of cardio-metabolic and liver disease	$359M	The Column Group, Prospect Venture Partners ... & 7 others	55/100